315 related articles for article (PubMed ID: 34972974)
1. Pulmonary Toxicities of Immunotherapy.
Altan M; Zhong L; Shannon VR; Sheshadri A
Adv Exp Med Biol; 2021; 1342():357-375. PubMed ID: 34972974
[TBL] [Abstract][Full Text] [Related]
2. Immune-Related Adverse Events: Pneumonitis.
Zhong L; Altan M; Shannon VR; Sheshadri A
Adv Exp Med Biol; 2020; 1244():255-269. PubMed ID: 32301020
[TBL] [Abstract][Full Text] [Related]
3. Immune-Related Adverse Events: Pneumonitis.
Jain A; Shannon VR; Sheshadri A
Adv Exp Med Biol; 2018; 995():131-149. PubMed ID: 30539509
[TBL] [Abstract][Full Text] [Related]
4. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
5. Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors.
Park H; Hatabu H; Ricciuti B; Aijazi SJ; Awad MM; Nishino M
Eur J Radiol; 2020 Nov; 132():109275. PubMed ID: 32949913
[TBL] [Abstract][Full Text] [Related]
6. [No hair loss, but colitis or pneumonitis: unique side effects of immune checkpoint inhibitors for cancer].
Steenbruggen TG; van den Heuvel MM; Blank CU; van Dieren JM; Haanen JB; Kok M
Ned Tijdschr Geneeskd; 2016; 160():A9873. PubMed ID: 27438388
[TBL] [Abstract][Full Text] [Related]
7. Expected and non-expected immune-related adverse events detectable by CT.
Ciccarese F; Piccinino A; Brocchi S; Balacchi C; Dall'Olio FG; Massari F; Rihawi K; Paccapelo A; Ardizzoni A; Golfieri R
Eur J Radiol; 2021 May; 138():109617. PubMed ID: 33676358
[TBL] [Abstract][Full Text] [Related]
8. Supportive care for patients undergoing immunotherapy.
Rapoport BL; van Eeden R; Sibaud V; Epstein JB; Klastersky J; Aapro M; Moodley D
Support Care Cancer; 2017 Oct; 25(10):3017-3030. PubMed ID: 28707167
[TBL] [Abstract][Full Text] [Related]
9. [Clinical Diagnosis and Treatment Recommendations for the Pneumonitis Associated with Immune Checkpoint Inhibitor].
Wang H; Guo X; Zhou J; Duan L; Si X; Zhang L; Li Y; Liu X; Wang M; Shi J; Zhang L
Zhongguo Fei Ai Za Zhi; 2019 Oct; 22(10):621-626. PubMed ID: 31650943
[TBL] [Abstract][Full Text] [Related]
10. Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer.
Owen DH; Wei L; Bertino EM; Edd T; Villalona-Calero MA; He K; Shields PG; Carbone DP; Otterson GA
Clin Lung Cancer; 2018 Nov; 19(6):e893-e900. PubMed ID: 30197259
[TBL] [Abstract][Full Text] [Related]
11. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.
Hryniewicki AT; Wang C; Shatsky RA; Coyne CJ
J Emerg Med; 2018 Oct; 55(4):489-502. PubMed ID: 30120013
[TBL] [Abstract][Full Text] [Related]
12. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis.
Wang H; Guo X; Zhou J; Li Y; Duan L; Si X; Zhang L; Liu X; Wang M; Shi J; Zhang L
Thorac Cancer; 2020 Jan; 11(1):191-197. PubMed ID: 31762218
[TBL] [Abstract][Full Text] [Related]
13. Imaging Findings in Immunotherapy-related Renal Toxicity.
Khauli MA; An TJ; Anderson MA
J Immunother; 2022 Apr; 45(3):162-166. PubMed ID: 34670254
[TBL] [Abstract][Full Text] [Related]
14. Radiographic features of pneumonitis in patients treated with immunotherapy compared to traditional chemotherapy for non-small cell lung cancer.
Capaccione KM; Huang S; D'souza B; Leb J; Luk L; Goldstein J; May B; Deng A; Salvatore MM
Clin Imaging; 2023 Jan; 93():106-112. PubMed ID: 35307225
[TBL] [Abstract][Full Text] [Related]
15. Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors.
Klein BA; Alves FA; de Santana Rodrigues Velho J; Vacharotayangul P; Hanna GJ; LeBoeuf NR; Shazib MA; Villa A; Woo SB; Sroussi H; Sonis S; Treister NS
Oral Dis; 2022 Jan; 28(1):9-22. PubMed ID: 34265157
[TBL] [Abstract][Full Text] [Related]
16. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
[TBL] [Abstract][Full Text] [Related]
17. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy.
Possick JD
Clin Chest Med; 2017 Jun; 38(2):223-232. PubMed ID: 28477635
[TBL] [Abstract][Full Text] [Related]
19. [Pneumonitis Induced by Immune Checkpoint Inhibitors].
Miyawaki E; Kenmotsu H
Gan To Kagaku Ryoho; 2018 Jul; 45(7):1021-1026. PubMed ID: 30042264
[TBL] [Abstract][Full Text] [Related]
20. Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society.
Johkoh T; Lee KS; Nishino M; Travis WD; Ryu JH; Lee HY; Ryerson CJ; Franquet T; Bankier AA; Brown KK; Goo JM; Kauczor HU; Lynch DA; Nicholson AG; Richeldi L; Schaefer-Prokop CM; Verschakelen J; Raoof S; Rubin GD; Powell C; Inoue Y; Hatabu H
Chest; 2021 Mar; 159(3):1107-1125. PubMed ID: 33450293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
